Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workersArticle Published on 2022-11-012022-11-15 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 진단, [키워드] age alcohol all age groups anti-RBD antibody antibody level antibody levels Antibody Response Antibody titer Asian baseline binding domain BNT162b2 BNT162b2 mRNA BNT162b2 vaccine Boosted vaccination booster dose booster vaccination conducted COVID-19 COVID-19 vaccine dose eight elevated Ethnic groups group healthcare worker Healthcare workers healthcare workers. healthy IgG information investigated Japan Japanese median median titer of BNT162b2 participant Prevent provided RBD response SARS-CoV-2 vaccine second dose serum shown significant increase the vaccine university vaccination Welfare [DOI] 10.1016/j.jiac.2022.07.006 PMC 바로가기
Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control studyArticle Published on 2022-11-012022-11-15 Journal: The Journal of Infection [Category] SARS, 진단, [키워드] cardiovascular disease case control study CoronaVac Effectiveness hospitalisation Infection Mortality of BNT162b2 omicron patients with diabete SARS-CoV-2 severe complications [DOI] 10.1016/j.jinf.2022.08.008 PMC 바로가기
Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasiasArticle Published on 2022-11-012022-11-15 Journal: British Journal of Haematology [Category] 진단, [키워드] age anti-CD38 antibodies antibody Antibody Response Antibody testing antibody titres Antigen binding domain BNT162b2 breadth Cell comparable coronavirus disease correlated COVID-19 COVID-19 vaccination demonstrated detectable dose dyscrasia elicit Genome healthy humoral immune immunization Immunocompromised Immunoglobulin Increasing initial Intervention investigated JNJ-78436735 maturation median mRNA vaccine mRNA-1273 Myeloma of BNT162b2 Patient patient population plasma Population proportion receiving Region response spike-specific T-cell Spike-specific T-cell responses Surface glycoprotein T-cell T-cell receptor T-cell Response TCR tested therapy underlying disease vaccination Vaccines Vaccines. [DOI] 10.1111/bjh.18434 PMC 바로가기
Immune response to SARS-CoV-2 mRNA vaccine in patients with psoriasis treated with biologicsArticle Published on 2022-11-012022-11-15 Journal: Clinical and experimental dermatology [Category] SARS, 진단, [키워드] antibody response against biologic COVID-19 vaccine dose Efficacy evaluate healthy controls monotherapy mRNA vaccine of BNT162b2 Patient Pfizer/BioNTech receiving SARS-CoV-2 treated treatment with biologics Vaccine [DOI] 10.1111/ced.15347 PMC 바로가기
The Peripheral Immune Landscape in a Patient with Myocarditis after the Administration of BNT162b2 mRNA VaccineArticle Published on 2022-10-312022-11-15 Journal: Molecules and cells [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] acute respiratory syndrome analysis approved BNT162b2 BNT162b2 mRNA vaccination causes cell clusters change changes in complications coronavirus Differentially expressed genes global public health help IL7R immune increased expression increased risk landscape Messenger RNA monocyte mononuclear cell mRNA myocarditis of BNT162b2 pandemic Pathogenesis Patient PBMC PBMCs peripheral Peripheral blood peripheral blood mononucleear cells reported Research SARS-CoV-2 Sequencing severe acute respiratory syndrome coronavirus 2 single-cell Single-cell RNA sequencing single-cell RNA sequencing. T cell receptor Transcriptome transcriptomic profile vaccinated individual vaccination Vaccine [DOI] 10.14348/molcells.2022.0031 PMC 바로가기
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyArticle Published on 2022-10-272022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Ad26.COV2.S Ad26.COV2.S vaccine age Analysis anti-SARS-CoV-2 Anti-spike antibody Antibody Response Antiretroviral therapy approved assays BNT162b2 CD4+ T-cell CD8+ T-cell ChAdOx1-S comparable Concentration conducted Control controls COVID-19 defined ELISPOT Endpoint Environment Final generally mild geometric HIV HIV-negative IFN-γ immunogenic immunogenicity Increased IQR less maintain male marker median age mRNA vaccination mRNA vaccine mRNA-1273 mRNA-based vaccines Netherland Netherlands of BNT162b2 PLWH predicted primary endpoint prospective cohort study Public reactogenicity receiving recipients reduced Registered remained required response SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 spike peptide SARS-CoV-2 vaccination SARS-CoV-2 vaccine secondary Serious Adverse Events serological response Sex suppressed T-cell Response the median the vaccine Trial vaccination Vaccine vaccine group Viral load with HIV [DOI] 10.1371/journal.pmed.1003979 PMC 바로가기
Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric studyArticle Published on 2022-10-212022-11-15 Journal: Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome addition Analysis analyzed Antibody titer attenuate Baricitinib BNT162b2 mRNA BNT162b2 mRNA vaccination BNT162b2 vaccine Combination controls coronavirus coronavirus disease COVID-19 COVID-19 vaccine disease domain dose Glucocorticoids healthy volunteer humoral immune response immunomodulatory Immunosuppressant immunosuppressants immunosuppressive immunosuppressive agent Immunosuppressive medication impair inhibitor inhibitors interleukin-17 interleukin-6 investigated Japanese Kagawa methotrexate much lower Necrosis of BNT162b2 Outpatient Patient patients treated reduced rheumatic disease SARS-CoV-2 SARS-CoV-2 spike protein second dose serum serum antibody significantly significantly lower Spike protein the patient therapeutic agent Treatment university Vaccine [DOI] 10.1097/MD.0000000000031288 PMC 바로가기
Priming conditions shape breadth of neutralizing antibody responses to sarbecovirusesArticle Published on 2022-10-212022-11-15 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] BNT162b2 BNT162b2 vaccine breadth Breakthrough infection Cohort Combination condition cross-neutralization cross-protective dose elicit highest immunized inactivated include individual Infection magnitude mRNA multiplex neutralization Neutralization assay neutralizing antibody Neutralizing antibody response of BNT162b2 omicron public health Receptor binding domain sarbecovirus sarbecovirus Sarbecoviruses SARS-CoV-1 SARS-CoV-1 infection SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant sera Sinopharm vaccination Vaccine Vaccine design Virus spike viruses [DOI] 10.1038/s41467-022-34038-6 PMC 바로가기
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancerArticle Published on 2022-10-182022-11-15 Journal: Cell Reports Medicine [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] addition Blood Blood cancer Breakthrough infection Cancer CAPTURE study COVID-19 COVID-19 vaccine Delta detectable dose greater immune response Infection Live virus marker microneutralization NAb titer NAbT Neutralizing Neutralizing antibodies Neutralizing antibody titer of BNT162b2 omicron Patient proportion risk SARS-CoV-2 SARS-CoV-2 variant severe COVID-19 disease T cell response T cells therapy vaccination vaccine dose variants of concern variants of concern. wild-type [DOI] 10.1016/j.xcrm.2022.100781 PMC 바로가기
Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2Article Published on 2022-10-182022-11-15 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] antibody antibody production appear BNT162b2 BNT162b2 mRNA vaccine convalescent correlated COVID-19 COVID-19 patients decrease detectable eight elicit functional generate Heterologous humoral humoral immune response Immunity immunization increase induce marker mRNA vaccination mRNA vaccine mucosal mucosal immune NAb Neutralizing neutralizing capacity of BNT162b2 omicron peaked progression proportion protective immune response RBD RBD-binding antibody reduced Saliva SARS-CoV-2 second dose second vaccination sera significantly Spike protein subsequent the RBD the S1 subunit the SARS-CoV-2 vaccinated individual vaccination Vaccine vaccinee vaccinees variant virus neutralizing titers VoC VOCs wildtype [DOI] 10.1371/journal.pone.0263861 PMC 바로가기